Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

Summary

This study was designed to provide continued access to BCX9930 for participants with Paroxysmal Nocturnal Hemoglobinuria (PNH) who had benefited from treatment with BCX9930 in another BioCryst-sponsored study for PNH who, in the opinion of the investigator, would benefit from continued treatment with BCX9930; who did not have access to other effective treatment options; and to monitor the safety of BCX9930 in participants continuing to receive BCX9930 for the treatment of PNH.

Timeline

Start

2023-01-18

Primary completion

2025-01-31

Completion

2025-01-31

Drugs

Indications